BASELINE CHARACTERISTICS OF PARTICIPANTS IN BAXASIA: PHASE 3 STUDY OF THE ALDOSTERONE SYNTHASE INHIBITOR BAXDROSTAT IN ADULTS WITH UNCONTROLLED OR RESISTANT HYPERTENSION PRIMARILY FROM ASIA

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/b03ef05b87f53c90d58a5cb4024dde07.pdf
BASELINE CHARACTERISTICS OF PARTICIPANTS IN BAXASIA: PHASE 3 STUDY OF THE ALDOSTERONE SYNTHASE INHIBITOR BAXDROSTAT IN ADULTS WITH UNCONTROLLED OR RESISTANT HYPERTENSION PRIMARILY FROM ASIA

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Hirotaka
Shibata
Hirotaka Shibata Hiro-405@cb3.so-net.ne.jp Oita University Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine Oita Japan *
Michel Azizi Michel.azizi@aphp.fr Hôpital Européen Georges Pompidou Hypertension Department Paris France -
Jenifer M. Brown jbrown35@bwh.harvard.edu Brigham and Women’s Hospital Department of Medicine, Division of Cardiovascular Medicine Boston United States -
Wei Duan wei.duan3@astrazeneca.com AstraZeneca R&D China, Biometrics and Data Science Beijing China -
Jamie P. Dwyer Jamie.dwyer@hsc.utah.edu University of Utah Division of Nephrology and Hypertension Salt Lake City United States -
John M. Flack Jflack47@siumed.edu Southern Illinois University and Springfield Memorial Hospital Departments of Medicine and Population Science and Policy, Division of General Internal Medicine, Hypertension Section Springfield United States -
Erika S. W. Jones eswjones@gmail.com Groote Schuur Hospital, University of Cape Town Department of Medicine, Division of Nephrology and Hypertension Cape Town South Africa -
Lei Liu Lylian.Liu1@astrazeneca.com AstraZeneca R&D China, Clinical Science Cardiovascular, Renal and Metabolism (CVRM) Shanghai China -
Shira Perl Shira.perl@astrazeneca.com AstraZeneca R&D BioPharmaceuticals, Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM) Gaithersburg United States -
Ji-Guang Wang jiguangwang@rjh.com.cn Ruijin Hospital, Shanghai Jiao Tong University School of Medicine The Shanghai Institute of Hypertension Shanghai China -
Junjie Wu jeremy.wu1@astrazeneca.com AstraZeneca R&D China, Clinical Science Cardiovascular, Renal and Metabolism (CVRM) Shanghai China -
Bryan Williams bryan.williams@ucl.ac.uk UCL Hospitals Biomedical Research Centre, University College London Institute of Cardiovascular Science and National Institute for Health Research London United Kingdom -